Central nervous system diseases and inflammation: The complement system in the CNS: Thinking again

Central Nervous System Diseases and Inflammation

Volumn , Issue , 2008, Pages 153-174

  Tenner, Andrea J ^a   Pisalyaput, Karntipa ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 49549107860     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-73894-9_8     Document Type: Chapter

References (138)

1. Afagh, A., Cummings, B.J., Cribbs, D.H., Cotman, C.W., and Tenner, A.J. (1996). Localization and cell association of C1q in Alzheimer's disease brain. Exp. Neurol. 138, 22-32
2. Aimone, J.B., Leasure, J.L., Perreau, V.M., and Thallmair, M. (2004). Spatial and temporal gene expression profiling of the contused rat spinal cord. Exp. Neurol. 189, 204-221
3. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G.M., Cooper, N.R., Eikelenboom, P., Emmerling, M., Fiebich, B.L., Finch, C.E., Frautschy, S., Griffin, W.S., Hampel, H., Hull, M., Landreth, G., Lue, L., Mrak, R., Mackenzie, I.R., McGeer, P.L., O'Banion, M.K., Pachter, J., Pasinetti, G., Plata-Salaman, C., Rogers, J., Rydel, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., Van Muiswinkel, F.L., Veerhuis, R., Walker, D., Webster, S., Wegrzyniak, B., Wenk, G., and Wyss-Coray, T. (2000). Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421
4. Anderson, A.J., Robert, S., Huang, W., Young, W., and Cotman, C.W. (2004). Activation of complement pathways after contusion-induced spinal cord injury. J. Neurotrauma 21, 1831-1846
5. Anderson, A.J., Najbauer, J., Huang, W., Young, W., and Robert, S. (2005). Upregulation of complement inhibitors in association with vulnerable cells following contusion-induced spinal cord injury. J. Neurotrauma 22, 382-397
6. Arnett, H.A., Wang, Y., Matsushima, G.K., Suzuki, K., and Ting, J.P. (2003). Functional genomic analysis of remyelination reveals importance of inflammation in oligodendrocyte regeneration. J. Neurosci. 23, 9824-9832
7. Barnum, S.R. (1995). Complement biosynthesis in the central nervous system. Crit. Rev. Oral Biol. Med. 6, 132-146
8. Barnum, S.R. and Szalai, A.J. (2006). Complement and demyelinating disease: No MAC needed? Brain Res. Brain Res. Rev. 52, 58-68
9. Baudouin, C., Peyman, G.A., Fredj-Reygrobellet, D., Gordon, W.C., Lapalus, P., Gastaud, P., and Bazan, N.G. (1992). Immunohistological study of subretinal membranes in age-related macular degeneration. Jpn. J. Ophthalmol. 36, 443-451
10. Benard, M., Gonzalez, B.J., Schouft, M.T., Falluel-Morel, A., Vaudry, D., Chan, P., Vaudry, H., and Fontaine, M. (2004). Characterization of C3a and C5a receptors in rat cerebellar granule neurons during maturation. Neuroprotective effect of C5a against apoptotic cell death. J. Biol. Chem. 279, 43487-43496
11. Bensa, J.C., Reboul, A., and Colomb, M.G. (1983). Biosynthesis in vitro of complement subcomponents C1q, C1s and C1 inhibitor by resting and stimulated human monocytes. Biochem. J. 216, 385-392
12. Bergamaschini, L., Rossi, E., Storini, C., Pizzimenti, S., Distaso, M., Perego, C., De Luigi, A., Vergani, C., and Grazia, D.S. (2004). Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-Amyloid accumulation in a mouse model of Alzheimer's disease. J. Neurosci. 24, 4181-4186
13. Blom, A.M., Kask, L., and Dahlback, B. (2001). Structural requirements for the complement regulatory activities of C4BP. J. Biol. Chem. 276, 27136-27144
14. Bobak, D.A., Gaither, T.G., Frank, M.M., and Tenner, A.J. (1987). Modulation of FcR function by complement: Subcomponent C1q enhances the phagocytosis of IgG-opsonized targets by human monocytes and culture-derived macrophages. J. Immunol. 138, 1150-1156.
15. Bohlson, S.S., Fraser, D.A., and Tenner, A.J. (2007). Complement proteins C1q and MBL are pattern recognition molecules that signal immediate and long-Term protective immune functions. Mol. Immunol. 44, 33-43
16. Boos, L., Campbell, I.L., Ames, R., Wetsel, R.A., and Barnum, S.R. (2004). Deletion of the complement anaphylatoxin c3a receptor attenuates, whereas ectopic expression of c3a in the brain exacerbates, experimental autoimmune encephalomyelitis. J. Immunol. 173, 4708-4714
17. Boos, L.A., Szalai, A.J., and Barnum, S.R. (2005). Murine complement C4 is not required for experimental autoimmune encephalomyelitis. Glia 49, 158-160
18. Botto, M., Dell'agnola, C., Bygrave, A.E., Thompson, E.M., Cook, H.T., Petry, F., Loos, M., Pandolfi, P.P., and Walport, M.J. (1998). Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 19, 56-59
19. Bracken, M.B. (2000). The use of methylprednisolone. J. Neurosurg. 93, 340-341
20. Bradt, B.M., Kolb, W.P., and Cooper, N.R. (1998). Complement-dependent proinflammatory properties of the Alzheimer's disease ? -peptide. J. Exp. Med. 188, 431-438
21. Carlson, S.L., Parrish, M.E., Springer, J.E., Doty, K., and Dossett, L. (1998). Acute inflammatory response in spinal cord following impact injury. Exp. Neurol. 151, 77-88
22. Chen, S., Frederickson, R.C., and Brunden, K.R. (1996). Neuroglial-mediated immunoinflammatory responses in Alzheimer's disease: Complement activation and therapeutic approaches. Neurobiol. Aging 17, 781-787
23. Dandoy-Dron, F., Guillo, F., Benboudjema, L., Deslys, J.P., Lasmezas, C., Dormont, D., Tovey, M.G., and Dron, M. (1998). Gene expression in scrapie. Cloning of a new scrapie-responsive gene and the identification of increased levels of seven other mRNA transcripts. J. Biol. Chem. 273, 7691-7697
24. Dhib-Jalbut, S., Arnold, D.L., Cleveland, D.W., Fisher, M., Friedlander, R.M., Mouradian, M.M., Przedborski, S., Trapp, B.D., Wyss-Coray, T., and Yong, V.W. (2006). Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J. Neuroimmunol. 176, 198-215
25. Dietzschold, B., Schwaeble, W., Schäfer, M.K.H., Hooper, D.C., Zehng, Y.M., Petry, F., Sheng, H., Fink, T., Loos, M., Koprowski, H., and Weihe, E. (1995). Expression of C1q, a subcomponent of the rat complement system, is dramatically enhanced in brains of rats with either Borna disease or experimental allergic encephalomyelitis. J. Neurol. Sci. 130, 11-16
26. Dyer, J.K., Bourque, J.A., and Steeves, J.D. (1998). Regeneration of brainstem-spinal axons after lesion and immunological disruption of myelin in adult rat. Exp. Neurol. 154, 12-22
27. Dyer, J.K., Bourque, J.A., and Steeves, J.D. (2005). The role of complement in immunological demyelination of the mammalian spinal cord. Spinal Cord 43, 417-425
28. Eikelenboom, P., Hack, C.E., Rozemuller, J.M., and Stam, F.C. (1989). Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch. B Cell Pathol. 56, 259-262
29. El-Agnaf, O.M., Nagala, S., Patel, B.P., and Austen, B.M. (2001). Non-fibrillar oligomeric species of the amyloid ABri peptide, implicated in familial British dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils. J. Mol. Biol. 310, 157-168
30. Ember, J.A., Jagels, M.A., and Hugli, T. (1998). Characterization of complement anaphylatoxins and biological responses. In The Human Complement System in Health and Disease, J.E. Volanakis and M.M. Frank, eds. (New York, NY: Marcel Dekker), pp. 241-284
31. Fonseca, M.I., Zhou, J., Botto, M., and Tenner, A.J. (2004). Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J. Neurosci. 24, 6457-6465
32. Fraser, D.A., Bohlson, S.S., Jasinskiene, N., Rawal, N., Palmarini, G., Ruiz, S., Rochford, R., and Tenner, A.J. (2006). C1q and MBL, components of the innate immune system, influence monocyte cytokine expression. J. Leukoc. Biol. 80, 107-116
33. Fraser, D.A., Arora, M., Bohlson, S.S., Lozano, E., and Tenner, A.J. (2007). Generation of inhibitory NFkappa B complexes and pCREB correlates with the anti-inflammatory activity of complement protein C1q in human monocytes. J. Biol. Chem. 282, 7360-7367.
34. Gao, H., Neff, T.A., Guo, R.F., Speyer, C.L., Sarma, J.V., Tomlins, S., Man, Y., Riedemann, N.C., Hoesel, L.M., Younkin, E., Zetoune, F.S., and Ward, P.A. (2005). Evidence for a functional role of the second C5a receptor C5L2. FASEB J. 19, 1003-1005
35. Gasque, P. (2004). Complement: A unique innate immune sensor for danger signals. Mol. Immunol. 41, 1089-1098
36. Gasque, P., Dean, Y.D., McGreal, E.P., VanBeek, J., and Morgan, B.P. (2000). Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 49, 171-186
37. Gavrilyuk, V., Kalinin, S., Hilbush, B.S., Middlecamp, A., McGuire, S., Pelligrino, D., Weinberg, G., and Feinstein, D.L. (2005). Identification of complement 5a-like receptor (C5L2) from astrocytes: Characterization of anti-inflammatory properties. J. Neurochem. 92, 1140-1149
38. Gerard, N.P., Lu, B., Liu, P., Craig, S., Fujiwara, Y., Okinaga, S., and Gerard, C. (2005). An antiinflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J. Biol. Chem. 280, 39677-39680
39. Gibson, G., Gunasekera, N., Lee, M., Lelyveld, V., El-Agnaf, O.M., Wright, A., and Austen, B. (2004). Oligomerization and neurotoxicity of the amyloid ADan peptide implicated in familial Danish dementia. J. Neurochem. 88, 281-290
40. Golde, T.E (2005). The Abeta hypothesis: Leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol. 15, 84-87
41. Goldsmith, S.K., Wals, P., Rozovsky, I., Morgan, T.E., and Finch, C.E. (1997). Kainic acid and decorticating lesions stimulate the synthesis of C1q protein in adult rat brain. J. Neurochem. 68, 2046-2052
42. Griffin, W.S. and Mrak, R.E. (2002). Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J. Leukoc. Biol. 72, 233-238
43. Grimsley, C. and Ravichandran, K.S. (2003). Cues for apoptotic cell engulfment: Eat-me, don't eat-me and come-get-me signals. Trends Cell Biol. 13, 648-656
44. Guo, R.F. and Ward, P.A. (2005). Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23, 821-852
45. Hageman, G.S., Luthert, P.J., Victor Chong, N.H., Johnson, L.V., Anderson, D.H., and Mullins, R.F. (2001). An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog. Retin. Eye Res. 20, 705-732
46. Hageman, G.S., Anderson, D.H., Johnson, L.V., Hancox, L.S., Taiber, A.J., Hardisty, L.I., Hageman, J.L., Stockman, H.A., Borchardt, J.D., Gehrs, K.M., Smith, R.J., Silvestri, G., Russell, S.R., Klaver, C.C., Barbazetto, I., Chang, S., Yannuzzi, L.A., Barile, G.R., Merriam, J.C., Smith, R.T., Olsh, A.K., Bergeron, J., Zernant, J., Merriam, J.E., Gold, B., Dean, M., and Allikmets, R. (2005). A common haplotype in the complement regulatory gene factor H (HF1/ CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. U.S.A 102, 7227-7232
47. Haines, J.L., Hauser, M.A., Schmidt, S., Scott, W.K., Olson, L.M., Gallins, P., Spencer, K.L., Kwan, S.Y., Noureddine, M., Gilbert, J.R., Schnetz-Boutaud, N., Agarwal, A., Postel, E.A., and Pericak-Vance, M.A. (2005). Complement factor H variant increases the risk of agerelated macular degeneration. Science 308, 419-420
48. Hanayama, R., Tanaka, M., Miyasaka, K., Aozasa, K., Koike, M., Uchiyama, Y., and Nagata, S. (2004). Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science 304, 1147-1150
49. Hawlisch, H., Belkaid, Y., Baelder, R., Hildeman, D., Gerard, C., and Kohl, J. (2005). C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity 22, 415-426
50. Heese, K., Hock, C., and Otten, U. (1998). Inflammatory signals induce neurotrophin expression in human microglial cells. J. Neurochem. 70, 699-707
51. Heller, T., Hennecke, M., Baumann, U., Gessner, J.E., zu Vilsendorf, A.M., Baensch, M., Boulay, F., Kola, A., Klos, A., Bautsch, W., and Kohl, J. (1999). Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. J. Immunol. 163, 985-994
52. Huang, J., Kim, L.J., Mealey, R., Marsh, Jr.H.C., Zhang, Y., Tenner, A.J., Connolly, E.S., Jr., and Pinsky, D.J. (1999). Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 285, 595-599
53. Jauneau, A.C., Ischenko, A., Chatagner, A., Benard, M., Chan, P., Schouft, M.T., Patte, C., Vaudry, H., and Fontaine, M. (2006). Interleukin 1b and anaphylatoxins exert a synergistic effect on NGF expression by astrocytes. J. Neuroinflammation. 3, 8
54. Jiang, H., Burdick, D., Glabe, C.G., Cotman, C.W., and Tenner, A.J. (1994). ? -Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol. 152, 5050-5059
55. Johnson, S.A., Lampert-Etchells, M., Pasinetti, G.M., Rozovsky, I., and Finch, C. (1992). Complement mRNA in the mammalian brain: Responses to Alzheimer's disease and experimental brain lesioning. Neurobiol. Aging 13, 641-648
56. Johnson, L.V., Leitner, W.P., Rivest, A.J., Staples, M.K., Radeke, M.J., and Anderson, D.H. (2002). The Alzheimer's A{beta}-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc. Natl. Acad. Sci. U.S.A. 99, 14682-14687
57. Klein, R.J., Zeiss, C., Chew, E.Y., Tsai, J.Y., Sackler, R.S., Haynes, C., Henning, A.K., Sangiovanni, J.P., Mane, S.M., Mayne, S.T., Bracken, M.B., Ferris, F.L., Ott, J., Barnstable, C., and Hoh, J. (2005). Complement factor H polymorphism in age-related macular degeneration. Science 308, 385-389
58. Koistinaho, M., Ort, M., Cimadevilla, J.M., Vondrous, R., Cordell, B., Koistinaho, J., Bures, J., and Higgins, L.S. (2001). Specific spatial learning deficits become severe with age in beta -Amyloid precursor protein transgenic mice that harbor diffuse beta - Amyloid deposits but do not form plaques. Proc. Natl. Acad. Sci. U.S.A. 98, 14675-14680
59. Konteatis, Z.D., Siciliano, S.J., Van, R.G., Molineaux, C.J., Pandya, S., Fischer, P., Rosen, H., Mumford, R.A., and Springer, M.S. (1994). Development of C5a receptor antagonists. Differential loss of functional responses. J. Immunol. 153, 4200-4205
60. Korb, L.C. and Ahearn, J.M. (1997). C1q binding directly and specifically to surface blebs of apoptotic human keratinocytes. J. Immunol. 158, 4525-4528
61. Kulkarni, A.P., Kellaway, L.A., Lahiri, D.K., and Kotwal, G.J. (2004). Neuroprotection from complement-mediated inflammatory damage. Ann. N.Y. Acad. Sci. 1035, 147-164
62. Lampert-Etchells, M., Pasinetti, G.M., Finch, C.E., and Johnson, S.A. (1993). Regional localization of cells containing complement C1q and C4 mRNAs in the frontal cortex during Alzheimer's disease. Neurodegeneration 2, 111-121
63. Lee, C.K., Weindruch, R., and Prolla, T.A. (2000). Gene-expression profile of the ageing brain in mice. Nat. Genet. 25, 294-297
64. Maller, J., George, S., Purcell, S., Fagerness, J., Altshuler, D., Daly, M.J., and Seddon, J.M. (2006). Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat. Genet. 38, 1055-1059
65. Markiewski, M.M., Mastellos, D., Tudoran, R., DeAngelis, R.A., Strey, C.W., Franchini, S., Wetsel, R.A., Erdei, A., and Lambris, J.D. (2004). C3a and C3b activation products of the third component of complement (C3) are critical for normal liver recovery after toxic injury. J. Immunol. 173, 747-754
66. Mastellos, D., Papadimitriou, J.C., Franchini, S., Tsonis, P.A., and Lambris, J.D. (2001). A novel role of complement: Mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J. Immunol. 166, 2479-2486
67. Matsuoka, Y., Picciano, M., Malester, B., LaFrancois, J., Zehr, C., Daeschner, J.M., Olschowka, J.A., Fonseca, M.I., O'Banion, M.K., Tenner, A.J., Lemere, C.A., and Duff, K. (2001). Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 158, 1345-1354
68. Mocco, J., Sughrue, M.E., Ducruet, A.F., Komotar, R.J., Sosunov, S.A., and Connolly, E.S., Jr. (2006). The complement system: A potential target for stroke therapy. Adv. Exp. Med. Biol. 586, 189-201
69. Möller, T., Nolte, C., Burger, R., Verkhratsky, A., and Kettenmann, H. (1997). Mechanisms of C5a and C3a complement fragment-induced [Ca2+]i signaling in mouse microglia. J. Neurosci. 17, 615-624
70. Morgan, B.P. and Gasque, P. (1997). Extrahepatic complement biosynthesis: Where, when and why? Clin. Exp. Immunol. 107, 1-7
71. Morgan, B.P., Griffiths, M., Khanom, H., Taylor, S.M., and Neal, J.W. (2004). Blockade of the C5a receptor fails to protect against experimental autoimmune encephalomyelitis in rats. Clin. Exp. Immunol. 138, 430-438
72. Mukherjee, P. and Pasinetti, G.M. (2001). Complement anaphylatoxin C5a neuroprotects through mitogen-Activated protein kinase-dependent inhibition of caspase 3. J. Neurochem. 77, 43-49
73. Nataf, S., Stahel, P.F., Davoust, N., and Barnum, S.R. (1999). Complement anaphylatoxin receptors on neurons: New tricks for old receptors? Trends Neurosci 22, 397-402
74. Nataf, S., Carroll, S.L., Wetsel, R.A., Szalai, A.J., and Barnum, S.R. (2000). Attenuation of experimental autoimmune demyelination in complement- deficient mice. J. Immunol. 165, 5867-5873
75. Navratil, J.S., Watkins, S.C., Wisnieski, J.J., and Ahearn, J.M. (2001). The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells. J. Immunol. 166, 3231-3239
76. Niculescu, T., Weerth, S., Niculescu, F., Cudrici, C., Rus, V., Raine, C.S., Shin, M.L., and Rus, H. (2004). Effects of complement C5 on apoptosis in experimental autoimmune encephalomyelitis. J. Immunol. 172, 5702-5706
77. Norsworthy, P.J., Fossati-Jimack, L., Cortes-Hernandez, J., Taylor, P.R., Bygrave, A.E., Thompson, R.D., Nourshargh, S., Walport, M.J., and Botto, M. (2004). Murine CD93 (C1qRp) contributes to the removal of apoptotic cells in vivo but is not required for C1q-mediated enhancement of phagocytosis. J. Immunol. 172, 3406-3414
78. O'Barr, S.A., Caguioa, J., Gruol, D., Perkins, G., Ember, J.A., Hugli, T., and Cooper, N.R. (2001). Neuronal expression of a functional receptor for the C5a complement activation fragment. J. Immunol. 166, 4154-4162
79. Oddo, S., Caccamo, A., Shepherd, J.D., Murphy, M.P., Golde, T.E., Kayed, R., Metherate, R., Mattson, M.P., Akbari, Y., and LaFerla, F.M. (2003). Triple-Transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421
80. Ogden, C.A., deCathelineau, A., Hoffmann, P.R., Bratton, D., Ghebrehiwet, B., Fadok, V.A., and Henson, P.M. (2001). C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J. Exp. Med. 194, 781-796
81. Ohmi, K., Greenberg, D.S., Rajavel, K.S., Ryazantsev, S., Li, H.H., and Neufeld, E.F. (2003). Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc. Natl. Acad. Sci. U.S.A. 100, 1902-1907
82. Ohno, M., Hirata, T., Enomoto, M., Araki, T., Ishimaru, H., and Takahashi, T.A. (2000). A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Mol. Immunol. 37, 407-412
83. Okinaga, S., Slattery, D., Humbles, A., Zsengeller, Z., Morteau, O., Kinrade, M.B., Brodbeck, R.M., Krause, J.E., Choe, H.R., Gerard, N.P., and Gerard, C. (2003). C5L2, a nonsignaling C5A binding protein. Biochemistry 42, 9406-9415
84. Osaka, H., Mukherjee, P., Aisen, P.S., and Pasinetti, G.M. (1999). Complement-derived anaphylatoxin C5a protects against glutamate- mediated neurotoxicity. J. Cell. Biochem. 73, 303-311
85. Pangburn, M.K. (2000). Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement. Immunopharmacology 49, 149-157
86. Pasinetti, G.M., Tocco, G., Sakhi, S., Musleh, W.D., DeSimoni, M.G., Mascarucci, P., Schreiber, S., Baudry, M., and Finch, C.E. (1996). Hereditary deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions. Neurobiol. Dis. 3, 197-204
87. Popovich, P.G., Wei, P., and Stokes, B.T. (1997). Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J. Comp Neurol. 377, 443-464
88. Proctor, L.M., Arumugam, T.V., Shiels, I., Reid, R.C., Fairlie, D.P., and Taylor, S.M. (2004). Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br. J. Pharmacol. 142, 756-764
89. Proctor, L.M., Woodruff, T.M., Sharma, P., Shiels, I.A., and Taylor, S.M. (2006). Transdermal pharmacology of small molecule cyclic C5a antagonists. Adv. Exp. Med. Biol. 586, 329-345
90. Qiao, F., Atkinson, C., Song, H., Pannu, R., Singh, I., and Tomlinson, S. (2006). Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am. J. Pathol. 169, 1039-1047
91. Rahpeymai, Y., Hietala, M.A., Wilhelmsson, U., Fotheringham, A., Davies, I., Nilsson, A.K., Zwirner, J., Wetsel, R.A., Gerard, C., Pekny, M., and Pekna, M. (2006). Complement: A novel factor in basal and ischemia-induced neurogenesis. EMBO J. 25, 1364-1374
92. Reboul, A., Prandini, M.H., Bensa, J.C., and Colomb, M.G. (1985). Characterization of C1q, C1s and C1 Inh synthesized by stimulated human monocytes in vitro. FEBS Lett. 190, 65-68
93. Reca, R., Mastellos, D., Majka, M., Marquez, L., Ratajczak, J., Franchini, S., Glodek, A., Honczarenko, M., Spruce, L.A., Janowska-Wieczorek, A., Lambris, J.D., and Ratajczak, M.Z. (2003). Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood 101, 3784-3793
94. Reiman, R., Gerard, C., Campbell, I.L., and Barnum, S.R. (2002). Disruption of the C5a receptor gene fails to protect against experimental allergic encephalomyelitis. Eur. J. Immunol. 32, 1157-1163
95. Reiman, R., Torres, A.C., Martin, B.K., Ting, J.P., Campbell, I.L., and Barnum, S.R. (2005). Expression of C5a in the brain Does not exacerbate experimental autoimmune encephalomyelitis. Neurosci. Lett. 390, 134-138
96. Rogers, J., Cooper, N.R., Webster, S., Schultz, J., McGeer, P.L., Styren, S.D., Civin, W.H., Brachova, L., Bradt, B., Ward, P., and Lieberburg, I. (1992). Complement activation by betaamyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 89, 10016-10020
97. Rostagno, A., Revesz, T., Lashley, T., Tomidokoro, Y., Magnotti, L., Braendgaard, H., Plant, G., Bojsen-Moller, M., Holton, J., Frangione, B., and Ghiso, J. (2002). Complement activation in chromosome 13 dementias. Similarities with Alzheimer's disease. J. Biol. Chem. 277, 49782-49790
98. Rostagno, A., Tomidokoro, Y., Lashley, T., Ng, D., Plant, G., Holton, J., Frangione, B., Revesz, T., and Ghiso, J. (2005). Chromosome 13 dementias. Cell Mol. Life Sci. 62, 1814-1825
99. Rus, H., Cudrici, C., and Niculescu, F. (2005a). C5b-9 complement complex in autoimmune demyelination and multiple sclerosis: Dual role in neuroinflammation and neuroprotection. Ann. Med. 37, 97-104
100. Rus, H., Cudrici, C., and Niculescu, F. (2005b). The role of the complement system in innate immunity. Immunol. Res. 33, 103-112
101. Rus, H., Cudrici, C., David, S., and Niculescu, F. (2006). The complement system in central nervous system diseases. Autoimmunity 39, 395-402
102. Sahu, A. and Lambris, J.D. (2001). Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol. Rev. 180, 35-48
103. Savill, J. and Fadok, V. (2000). Corpse clearance defines the meaning of cell death. Nature 407, 784-788
104. Scott, R.S., McMahon, E.J., Pops, S.M., Reap, E.A., Caricchio, R., Cohen, P.L., Earp, H.S., and Matsushima, G.K. (2001). Phagocytosis and clearance of apoptotic cells is mediated by mer. Nature 411, 207-211
105. Sewell, D.L., Nacewicz, B., Liu, F., Macvilay, S., Erdei, A., Lambris, J.D., Sandor, M., and Fabry, Z. (2004). Complement C3 and C5 play critical roles in traumatic brain cryoinjury: Blocking effects on neutrophil extravasation by C5a receptor antagonist. J. Neuroimmunol. 155, 55-63
106. Shen, Y., Li, R., McGeer, E.G., and McGeer, P.L. (1997). Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 769, 391-395
107. Singhrao, S.K., Neal, J.W., Morgan, B.P., and Gasque, P. (1999). Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp. Neurol. 159, 362-376
108. Song, W.C. (2004). Membrane complement regulatory proteins in autoimmune and inflammatory tissue injury. Curr. Dir. Autoimmun. 7, 181-199
109. Spitzer, D., Unsinger, J., Bessler, M., and Atkinson, J.P. (2004). ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. Mol. Immunol. 40, 911-919
110. Spitzer, D., Wu, X., Ma, X., Xu, L., Ponder, K.P., and Atkinson, J.P. (2006). Cutting edge: Treatment of complement regulatory protein Deficiency by retroviral in vivo gene therapy. J. Immunol. 177, 4953-4956
111. Streit, W.J. (2004). Microglia and Alzheimer's disease pathogenesis. J. Neurosci. Res. 77, 1-8
112. Streit, W.J., Semple-Rowland, S.L., Hurley, S.D., Miller, R.C., Popovich, P.G., and Stokes, B.T. (1998). Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis. Exp. Neurol. 152, 74-87
113. Strohmeyer, R., Shen, Y., and Rogers, J. (2000). Detection of complement alternative pathway mRNA and proteins in Alzheimer's disease brain. Mol. Brain Res. 81, 7-18
114. Stuart, L.M., Takahashi, K., Shi, L., Savill, J., and Ezekowitz, R.A. (2005). Mannose-binding lectin-deficient mice display defective apoptotic cell clearance but no autoimmune phenotype. J. Immunol. 174, 3220-3226
115. Takahashi, R.H., Milner, T.A., Li, F., Nam, E.E., Edgar, M.A., Yamaguchi, H., Beal, M.F., Xu, H., Greengard, P., and Gouras, G.K. (2002). Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am. J. Pathol. 161, 1869-1879
116. Tan, J., Town, T., Paris, D., Mori, T., Suo, Z., Crawford, F., Mattson, M.P., Flavell, R.A., and Mullan, M. (1999). Microglial activation resulting from CD40-CD40L interaction after ? -Amyloid stimulation. Science 286, 2352-2355
117. Tanzi, R.E. and Bertram, L. (2005). Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective. Cell 120, 545-555
118. Taylor, P.R., Carugati, A., Fadok, V.A., Cook, H.T., Andrews, M., Carroll, M.C., Savill, J.S., Henson, P.M., Botto, M., and Walport, M.J. (2000). A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J. Exp. Med. 192, 359-366
119. Tenner, A.J. and Fonseca, M.I. (2006). The double-edged flower: Roles of complement protein C1q in neurodegenerative diseases. Adv. Exp. Med. Biol. 586, 153-176
120. Tocco, G., Musleh, W., Sakhi, S., Schreiber, S.S., Baudry, M., and Pasinetti, G.M. (1997). Complement and glutamate neurotoxicity. Genotypic influences of C5 in a mouse model of hippocampal neurodegeneration. Mol. Chem. Neuropathol. 31, 289-300
121. Todd, R.J., Volmar, C.H., Dwivedi, S., Town, T., Crescentini, R., Crawford, F., Tan, J., and Mullan, M. (2004). Behavioral effects of CD40-CD40L pathway disruption in aged PSAPP mice. Brain Res. 1015, 161-168
122. Van Beek, J., Nicole, O., Ali, C., Ischenko, A., MacKenzie, E.T., Buisson, A., and Fontaine, M. (2001). Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death. Neuroreport 12, 289-293
123. Van Beek, J., Elward, K., and Gasque, P. (2003). Activation of complement in the central nervous system: Roles in neurodegeneration and neuroprotection. Ann. N.Y. Acad. Sci. 992, 56-71
124. Vandivier, R.W., Ogden, C.A., Fadok, V.A., Hoffmann, P.R., Brown, K.K., Botto, M., Walport, M.J., Fisher, J.H., Henson, P.M., and Greene, K.E. (2002). Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: Calreticulin and CD91 as a common collectin receptor complex. J. Immunol. 169, 3978-3986
125. Vanguri, P., Koski, C.L., Silverman, B., and Shin, M.L. (1982). Complement activation by isolated myelin: Activation of the classical pathway in the absence of myelin-specific antibodies. Proc. Natl. Acad. Sci. U.S.A. 79, 3290-3294
126. Walker, D.G. and McGeer, P.L. (1992). Complement gene expression in human brain: Comparison between normal and Alzheimer disease cases. Brain Res. Mol. Brain Res. 14, 109-116
127. Walport, M.J. (2001). Complement. Second of two parts. N. Engl. J. Med. 344, 1140-1144
128. Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., and Selkoe, D.J. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-Term potentiation in vivo. Nature 416, 535-539
129. Walsh, D.M., Townsend, M., Podlisny, M.B., Shankar, G.M., Fadeeva, J.V., Agnaf, O.E., Hartley, D.M., and Selkoe, D.J. (2005). Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-Term potentiation. J. Neurosci. 25, 2455-2462
130. Watson, M.D., Roher, A.E., Kim, K.S., Spiegel, K., and Emmerling, M.R. (1997). Complement interactions with amyloid-? 1-42: A nidus for inflammation in AD brains. Amyloid: Int. J. Exp. Clin. Invest. 4, 147-156
131. Webster, S., Lue, L.F., Brachova, L., Tenner, A.J., McGeer, P.L., Terai, K., Walker, D.G., Bradt, B., Cooper, N.R., and Rogers, J. (1997). Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Aging 18, 415-421
132. Woodruff, T.M., Arumugam, T.V., Shiels, I.A., Reid, R.C., Fairlie, D.P., and Taylor, S.M. (2003). A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J. Immunol. 171, 5514-5520
133. Woodruff, T.M., Arumugam, T.V., Shiels, I.A., Reid, R.C., Fairlie, D.P., and Taylor, S.M. (2004). Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemiareperfusion in rats. J. Surg. Res. 116, 81-90
134. Woodruff, T.M., Crane, J.W., Proctor, L.M., Buller, K.M., Shek, A.B., de, V.K., Pollitt, S., Williams, H.M., Shiels, I.A., Monk, P.N., and Taylor, S.M. (2006). Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J. 20, 1407-1417
135. Wyss-Coray, T. and Mucke, L. (2002). Inflammation in neurodegenerative disease-A doubleedged sword. Neuron 35, 419-432
136. Wyss-Coray, T., Yan, F., Lin, A.H., Lambris, J.D., Alexander, J.J., Quigg, R.J., and Masliah, E. (2002). Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. U.S.A. 99, 10837-10842
137. Yao, J., Harvath, L., Gilbert, D.L., and Colton, C.A. (1990). Chemotaxis by a CNS macrophage, the microglia. J. Neurosci. Res. 27, 36-42
138. Yao, Y., Chinnici, C., Tang, H., Trojanowski, J.Q., Lee, V.M., and Pratico, D. (2004). Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. J. Neuroinflammation 1, 21